June 23, 2003

8 Min Read
References


References
6/23/03 Digestion

  1. Kocian J. "[Lactobacilli in the treatment of dyspepsia due to dysmicrobia of various causes.]" (Article in Czech) Vnitr Lek. 40, 2:79-83, 1994.

  2. Bennet R et al. "The fecal microflora of 1-3-month-old infants during treatment with eight oral antibiotics." Infection. 30, 3:158-60, 2002.

  3. Marteau P et al. "Probiotics and intestinal health effects: a clinical perspective." Br J Nutr. 88 Suppl 1:S51-7, 2002. www.cabi-publishing.org/journals/bjn.

  4. Armuzzi A et al. "Effect of Lactobacillus GG supplementation on antibiotic-associated gastrointestinal side effects during Helicobacter pylori eradication therapy: a pilot study." Digestion. 63, 1:1-7, 2001. http://content.karger.com/ProdukteDB/produkte.asp?Aktion=JournalHome&ProduktNr=223838.

  5. Sullivan A, Nord CE. "The place of probiotics in human intestinal function." Int J Antimicrob Agents. 20, 5:313-9, 2002. www.harcourt-international.com/journals/ijaa.

  6. Henriksson, Conway. "Isolation of human faecal bifidobacteria which reduce signs of Salmonella infection when orogastrically dosed to mice." J Appl Microbiol. 90:223-8, 2001. www.blackwell-synergy.com.

  7. Asahara T et al. "Increased resistance of mice to Salmonella enterica serovar Typhimurium infection by symbiotic administration of Bifidobacteria and transgalactosylated oligosaccharides." J Appl Microbiol. 91, 6:985-96, 2001. www.blackwell-synergy.com.

  8. Swanson KS et al. "Fructooligosaccharides and Lactobacillus acidophilus modify gut microbial populations, total tract nutrient digestibility and fecal protein catabolite concentrations in healthy adult dogs." J Nutr. 132, 12:3721-31, 2002. www.nutrition.org.

  9. Bornet FR et al. "Nutritional aspects of short-chain fructooligosaccharides: a natural occurrence, chemistry, physiology and health implications." Dig Liver Dis. 34 Suppl 2:S111-20, 2002. www.elsevier.com/locate/dld.

  10. Hopkins MJ, Macfarlane GT. "Nondigestible oligosaccharides enhance bacterial colonization resistance against Clostridium difficile in vitro." Appl Environ Microbiol. 69, 4:1920-7, 2003. http://aem.asm.org.

  11. Kruse HP et al. "Effects of inulin of faecal bifidobacteria in human subjects." Br J Nutr. 82, 5:375-82, 1999. www.cabi-publishing.org/journals/bjn.

  12. Karnsakul W et al. "Disaccharidase activities in dyspeptic children: biochemical and molecular investigations of maltase-glucoamylase activity." J Pediatr Gastroenterol Nutr. 35, 4:551-6, 2002. www.jpgn.org.

  13. Suarez F et al. "Pancreatic supplements reduce symptomatic response of healthy subjects to a high fat meal." Dig Dis Sci. 44, 7:1317-21, 1999. www.kluweronline.com/issn/0163-2116/current.

  14. Bisignano G et al. "In vitro antibacterial activity of some aliphatic aldehydes from Olea europaea L." FEMS Microbiol Lett. 198, 1:9-13, 2001. www.sciencedirect.com/science/journal/03781097.

  15. Bisignano G et al. "On the in-vitro antimicrobial activity of oleuropein and hydroxytyrosol." J Pharm Pharmacol. 51, 8:971-4, 1999. http://jpp.pharmpress.com/content/html/index.htm.

  16. Wolfe MM et al. "Gastrointestinal toxicity of nonsteroidal anti-inflammatory drugs." NEJM. 340, 24:1888-99, 1999. http://content.nejm.org.

  17. Laine L. "Approaches to nonsteroidal anti-inflammatory drug use and the high-risk patient." Gastroenterology. 120:594-606, 2001. www.gastrojournal.org.

  18. Yoshida N et al. "Role of elastase and active oxygen species in gastric mucosal injury induced by aspirin administration in Helicobacter pylori-infected Mongolian gerbils." Aliment Pharmacol Ther. 16, Suppl 2:191-7, 2002.

  19. Naito Y et al. "Effects of polaprezinc on lipid peroxidation, neutrophil accumulation, and TNF-alpha expression in rats with aspirin-induced gastric mucosal injury." Dig Dis Sci. 46, 4:845-51, 2001. www.kluweronline.com/issn/0163-2116/current.

  20. Suzuki H et al. "Polaprezinc attenuates the Helicobacter pylori-induced gastric mucosal leucocyte activation in Mongolian gerbils--a study using intravital videomicroscopy." Aliment Pharmacol Ther. 15:715-25, 2001.

  21. Matsukura T, Tanaka H. "Applicability of zinc complex of L-carnosine for medical use." Biochemistry (Moscow). 65, 7:817-23, 2000. www.protein.bio.msu.su/biokhimiya.

  22. Feiz HR, Mobarhan S. "Does vitamin C intake slow the progression of gastric cancer in Helicobacter pylori-infected populations." Nutr Rev. 60, 1:34-6, 2002. www.ilsi.org/publications/reviews.html.

  23. Dabrowska-Ufniarz E et al. "Vitamin C concentration in gastric juice in patients with precancerous lesions of the stomach and gastric cancer." Med Sci Monit. 8, 2:CR96-103, 2002. www.medscimonit.com/medscimonit.

  24. Sjunnesson H et al. "High intake of selenium, beta-carotene, and vitamins A, C and E reduce growth of Helicobacter pylori in the guinea pig." Comp Med. 51, 5:418-23, 2001. www.aalas.org/education/publications/cmonline.htm.

  25. Akyon Y. "Effect of antioxidants on the immune response of Helicobacter pylori." Clin Microbiol Infect. 8, 7:438-41, 2002. www.blackwell-synergy.com.

  26. Fukai T et al. "Anti-Helicobacter pylori flavonoids from licorice extract." Life Sci. 71, 12:1449-63, 2002. www.sciencedirect.com/science/journal/00243205.

  27. Borrelli F, Izzo AA. "The plant kingdom as a source of anti-ulcer remedies." Phytother Res. 14, 8:581-91, 2000. www.interscience.wiley.com/jpages/0951-418X.

  28. Simopoulos AP. "Omega-3 fatty acids in inflammation and autoimmune diseases." J Am Coll Nutr. 21, 6:495-505, 2002. www.am-coll-nutr.org/jacn/jacn.htm.

  29. Gil A. "Polyunsaturated fatty acids and inflammatory diseases." Biomed Pharmacother. 56, 8:388-96, 2002. www.elsevier.nl/inca/publications/store/5/0/5/8/1/0.

  30. Belluzzi A. "N-3 fatty acids for the treatment of inflammatory bowel diseases." Proc Nutr Soc. 61, 3:391-5, 2002. www.cabi-publishing.org/journals/pns.

  31. Nieto N et al. "Dietary polyunsaturated fatty acids improve histological and biochemical alterations in rats with experimental ulcerative colitis." J Nutr. 132, 1:11-9, 2002. www.nutrition.org.

  32. Geerling BJ et al. "Nutritional supplementation with N-3 fatty acids and antioxidants in patients with Crohn's disease in remission: effects on antioxidant stats and fatty acid profile." Inflamm Bowel Dis. 6, 2:77-84, 2000. www.ccfa.org/physician/table7.htm.

  33. Middleton SJ et al. "A double-blind, randomized, placebo-controlled trial of essential fatty acid supplementation in the maintenance of remission of ulcerative colitis." Aliment Pharmacol Ther. 16, 6:1131-5, 2002.

  34. Thomas PD et al. "Dietary bioactive peptides in maintaining intestinal integrity and function." Am J Gastroenterol. 96, 9:S311, 2001. www.amjgastro.com.

  35. Nichols TW et al. "Dietary peptides from hydrolyzed white fish in maintaining intestinal integrity and function in inflammatory bowel disease." Peptides. 108, 1:31, 2002. www.sciencedirect.com/science/journal/01969781.

  36. Macfarlane GT, Cummings JH. "Probiotics, infection and immunity." Curr Opin Infect Dis. 15, 5:501-6, 2002. www.co-infectiousdiseases.com.

  37. Heller F, Duchmann R. "Intestinal flora and mucosal immune responses." Int J Med Microbiol. 293, 1:77-86, 2003. www.urbanfischer.de/journals/ijmm/bakteriol.htm.

  38. Gionchetti P et al. "Probiotics--role in inflammatory bowel disease." Dig Liver Dis. 32 Suppl 2:S58-62, 2002. www.elsevier.com/locate/dld.

  39. Fujiwara M et al. "Inhibitory effects of Bifidobacterium longum on experimental ulcerative colitis induced in mice by synthetic dextran sulfate sodium." Digestion. 67, 1-2:90-5, 2003. http://content.karger.com/ProdukteDB/produkte.asp?Aktion=JournalHome&ProduktNr=223838.

  40. Gionchetti P et al. "Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial." Gastroenterology. 124, 5:1202-9, 2003. www.gastrojournal.org.

  41. Sen S et al. "Effect of Lactobacillus plantarum 299v on colonic fermentation and symptoms of irritable bowel syndrome." Dig Dis Sci. 47, 11:2615-20, 2002. www.kluweronline.com/issn/0163-2116/current.

  42. Madden JA, Hunter JO. "A review of the role of the gut microflora in irritable bowel syndrome and the effects of probiotics." Br J Nutr. 88 Suppl 1:S67-72, 2002. www.cabi-publishing.org/journals/bjn.

  43. Nobaek S et al. "Alteration of intestinal microflora is associated with reduction in abdominal bloating and pain in patients with irritable bowel syndrome." Am J Gastroenterol. 95, 5:1231-8, 2000. www.amjgastro.com.

  44. O'Sullivan MA, O'Morain CA. "Bacterial supplementation in the irritable bowel syndrome. A randomized double-blind placebo-controlled crossover study." Dig Liver Dis. 32, 4:294-301, 2000. www.elsevier.com/locate/dld.

  45. Kim HJ et al. "A randomized controlled trial of a probiotic, VSL#3 (marketed by VSL Pharmaceuticals), on gut transit and symptoms in diarrhoea-predominant irritable bowel syndrome." Aliment Pharmacol Ther. 17, 7:895-904, 2003.

  46. Ouwehand AC et al. "Effect of probiotics on constipation, fecal azoreductase activity and fecal mucin content in the elderly." Ann Nutr Metab. 46, 3-4:159-62, 2002. www.karger.com/anm.

  47. McIntosh GH et al. "Whole-grain rye and wheat foods and markers of bowel health in overweight middle-aged men." Am J Clin Nutr. 77, 4:967-74, 2003. www.ajcn.org.

  48. Fernandez-Banares F et al. "Randomized clinical trial of Plantago ovata seeds (dietary fiber) as compared with mesalamine in maintaining remission in ulcerative colitis: Spanish Group for the Study of Crohn's Disease and Ulcerative Colitis (GETECCU)." Am J Gastroenterol. 94, 2:427-33, 1999. www.amjgastro.com.

  49. Marteau P, Boutron-Ruault MC. "Nutritional advantages of probiotics and prebiotics." Br J Nutr. 87, Suppl 2:S153-7, 2002. www.cabi-publishing.org/journals/bjn.

  50. Bornet FR et al, op. cit., 2002.

  51. Kaur N, Gupta AK. "Applications of inulin and oligofructose in health and nutrition." J Biosci. 27, 7:703-14, 2002. www.ias.ac.in/jbiosci.

  52. Flamm G et al. "Inulin and oligofructose as dietary fiber: a review of the evidence." Crit Rev Food Sci Nutr. 41, 5:353-62, 2001. www.sciencedirect.com/science/journal/10408398.

  53. Cummings JH, Macfarlane GT. "Gastrointestinal effects of prebiotics." Br J Nutr. 87 Suppl 2:S145-51, 2002. www.cabi-publishing.org/journals/bjn.

  54. Correa-Matos NJ et al. "Fermentable fiber reduces recovery time and improves intestinal function in piglets following Salmonella typhimurium infection." J Nutr. 133, 6:1845-52, 2003. www.nutrition.org.

  55. Cherbut C et al. "The prebiotic characteristics of fructooligosaccharides are necessary for reduction of TNBS-induced colitis in rats." J Nutr. 133:21-7, 2003. www.nutrition.org.

  56. Zhong J et al. "Studies on the effects of polydextrose intake on physiologic functions in Chinese people." Am J Clin Nutr. 72, 6:1503-9, 2000. www.ajcn.org.

  57. Simadibrata M et al. "Examination of small bowel enzymes in chronic diarrhea." J Gastroenterol Hepatol. 18, 1:53-6, 2003. www.blackwellpublishing.com/journals/jgh.

  58. Thomson AB et al. "Small bowel review: normal physiology part 1." Dig Dis Sci. 46, 12:2567-87, 2001. www.kluweronline.com/issn/0163-2116/current.

  59. Kline RM et al. "Enteric-coated, pH-dependent peppermint oil capsules for the treatment of irritable bowel syndrome in children." J Pediatr. 138, 1:125-8, 2001. www.mosby.com/jpeds.

  60. Walker AF et al. "Artichoke leaf extract reduces symptoms of irritable bowel syndrome in a post-marketing surveillance study." Phytother Res. 15, 1:58-61, 2001. www.interscience.wiley.com/jpages/0951-418X.

  61. Sandoval-Chacon M et al. "Antiinflammatory actions of cat's claw: the role of NF-kappaB." Aliment Pharmacol Ther. 12, 12:1279-89, 1998.

Subscribe and receive the latest insights on the health and nutrition industry.
Join 37,000+ members. Yes, it's completely free.

You May Also Like